Literature DB >> 839365

Suppressibility of glucagon secretion by glucose in juvenile diabetes.

M A Sperling, K Aleck, S Voina.   

Abstract

The suppressibility of plasma glucagon concentrations by glucose was investigated in normal and diabetic children. Fasting concentrations of plasma glucagon were similar in normal and in diabetic children despite the hyperglycemia of the latter. Infusion of glucose promptly suppressed glucagon values in the normal as well as in the diabetic children pretreated with half of their usual morning dose of insulin. Glucose alone, however, did not suppress plasma glucagon in diabetic patients, despite the attainment of significant hyperglycemia. Administration of insulin during an ongoing glucose infusion in the diabetic patients lowered their blood glucose concentration; the concentration of glucagon rose transiently when the glucose concentration fell. These data confirm the existence of relative hyperglucagonemia inappropriate for the degree of blood glucose concentration in diabetic children deprived of insulin. The data also suggest that this hyperglucagonemia is secondary to insulin deficiency and suppressibility of glucagon by glucose can be restored by insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 839365     DOI: 10.1016/s0022-3476(77)80363-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Pleotropic Acute and Chronic Effects of Leptin to Reverse Type 1 Diabetes.

Authors:  Rachel J Perry
Journal:  Postdoc J       Date:  2017-01

2.  Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.

Authors:  Rebecca J Brown; Ninet Sinaii; Kristina I Rother
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

3.  Abnormal regulation of glucagon secretion by human islet alpha cells in the absence of beta cells.

Authors:  Wei Liu; Tatsuya Kin; Siuhong Ho; Craig Dorrell; Sean R Campbell; Ping Luo; Xiaojuan Chen
Journal:  EBioMedicine       Date:  2019-11-26       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.